var data={"title":"Fat emulsion (soybean, medium-chain triglyceride, olive, and fish oils; Smoflipid): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fat emulsion (soybean, medium-chain triglyceride, olive, and fish oils; Smoflipid): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/701790?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information\" class=\"drug drug_general\">see &quot;Fat emulsion (soybean, medium-chain triglyceride, olive, and fish oils; Smoflipid): Drug information&quot;</a> and <a href=\"topic.htm?path=fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fat emulsion (soybean, medium-chain triglyceride, olive, and fish oils; Smoflipid): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48869238\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Death in preterm infants:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Deaths in preterm infants after infusion of intravenous (IV) lipid emulsions have been reported in the medical literature. Autopsy findings included intravascular fat accumulation in the lungs. Preterm infants and low-birth-weight infants have poor clearance of IV lipid emulsion and increased free fatty acid plasma levels following lipid emulsion infusion.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F47022752\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Smoflipid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22549120\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Smoflipid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22874952\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Caloric Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49160709\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Parenteral Nutrition</b>: Limited data available: IV: Initial 1g/kg/day; increasing by 0.5 to 1 g/kg/day as tolerated up to 3.6 g/kg/day (Biesboer 2016; Deshphande 2014, Savini 2013, Skouroliakou 2012). Dosing based on experience in over 180 premature neonates (minimum reported GA: 23 weeks) who had fish oil-based lipids initiated at the time parenteral nutrition was started; fish oil-based lipids were reported to be well-tolerated with a reduction in oxidative stress indicators and decreased incidence of cholestasis in some cases. A meta-analysis, however, did not find fish oil-based lipids to be beneficial in preventing cholestasis (Park 2015). In the largest prospective, observational study in preterm neonates (total: n=282; GA: 23 to 36 weeks; birthweight: 530 to 2,490 g), VLBW neonates receiving fish oil-based lipids (n=54) were found to have a lower incidence of BPD and better lipid profile than those receiving soybean-based lipids; the group receiving fish oil-based lipids also had a lower incidence of cholestasis; however, this was not statistically significant (Skouroliakou 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22874957\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information\" class=\"drug drug_general\">see &quot;Fat emulsion (soybean, medium-chain triglyceride, olive, and fish oils; Smoflipid): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Parenteral Nutrition: </b>Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children: IV: Usual reported dose: 2 g/kg/day; reported range: 1.5 to 3.5 g/kg/day with the majority of experience in home parenteral nutrition patients; dosing based on a prospective, randomized, double-blind active controlled trial, and a retrospective cohort comparison. The randomized controlled trial enrolled 28 subjects (age range: 5 months to 11 years) requiring home TPN for &ge;4 weeks and randomly assigned them to receive either fish oil-based lipids (active group: n=15) or plant-based lipids (control group: n=13) as part of the PN regimen; fish oil-based lipids were found to be well-tolerated and resulted in a significant decrease in total bilirubin compared to an increased total bilirubin seen in the plant-based lipid group; liver function parameters also trended lower in the active group compared to the control group; the active group also had significantly increased omega-3 fatty acids and alpha-tocopherol concentrations (Goulet 2010). The retrospective study included eight children with elevated total bilirubin secondary to TPN (age: Median: 7.5 months; range: 3 months to 3.2 years) who were changed to fish oil-based lipids and then compared  to a similar historic cohort (n=9) who continued receiving standard plant-based lipids; after 6 months of therapy, data showed  a significant decrease in the bilirubin in the fish oil-based lipid group compared to the historic cohort which experienced an increase in bilirubin; 62.5% of patients receiving fish oil-based lipids had a complete resolution of jaundice compared to 22% of the cohort group (Muhammed 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents: Limited data available: IV: Initial: 1 g/kg/day; increase gradually to 2 g/kg/day (SMOFlipid prescribing information [Australia 2016]). <b>Note:</b> US labeling for adults has a maximum daily dose of 2.5 g/kg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Parenteral Nutrition</b>: IV: 1 to 2 g/kg/day; daily dose may be infused over 12 to 24 hours; maximum daily dose: 2.5 g/kg/<b>day</b>. <b>Note:</b> Fat emulsion should not exceed a maximum of 60% of the total daily calories.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Monitor liver function closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F47022753\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Emulsion, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Smoflipid: 20% (100 mL, 250 mL, 500 mL) [contains egg phospholipids (egg lecithin)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F47022751\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22874958\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Prior to opening the overwrap, the integrity indicator should be inspected. If the indicator is black, the overwrap is damaged; do not use. Gently invert bag prior to use. Do not use if discolored or if the emulsion contains a precipitate, phase separation, or there are leaks in the bag.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Administer by IV infusion via peripheral line or central venous line using DEHP-free administration sets and lines. All fat emulsion infusions should be filtered whether part of an admixture or infused separately using a 1.2-micron in-line filter only (ISMP 2016). To prevent air embolism, use a nonvented infusion set or close the vent on a vented set, avoid multiple connections, do not connect flexible bags in series, fully evacuate residual gas in the bag prior to administration, do not pressurize the flexible bag to increase flow rates, and if administration is controlled by a pumping device, turn off pump before the bag runs dry. Change tubing after each infusion. May be simultaneously infused with amino acid dextrose mixtures by means of Y-connector located near infusion site (flow rates of each solution should be controlled separately by infusion pumps). When administered with dextrose and amino acids, the choice of a central or peripheral infusion depends on the osmolarity of the final infusate (osmolarity &ge;900 mOsm/L must be infused through a central vein).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pediatric: In reported experience, infusions have been over 24 hours in neonates, and over 12 to 24 hours in older pediatric patients. The maximum rate of infusion suggested: Neonates: 0.125 g/kg/hour, and in infants and children: 0.15 g/kg/hour (Biesboer 2016; SMOFlipid prescribing information [Australia 2016])</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Adults: Initiate at 0.5 mL/minute for 15 to 30 minutes; if tolerated may gradually increase to a maximum rate of 0.5 mL/kg/hour</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22781926\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Store in overpouch until ready for use; once removed from overpouch, use immediately. If not used immediately, the manufacturer suggests storing at 2&deg;C to 8&deg;C (35.6&deg;F to 46.4&deg;F) for no longer than 24 hours; after removal from refrigeration, the emulsion should be infused within 24 hours. Do not freeze. Avoid excessive heat.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22874953\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Source of calories and essential fatty acids for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22801482\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hypertension, tachycardia, thrombophlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyperglycemia, increased gamma-glutamyl transferase, increased serum triglycerides</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, cholestasis, diarrhea, dysgeusia, dyspepsia, flatulence, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, C-reactive protein increased, leukocytosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal hepatic function tests, increased serum alkaline phosphatase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Catheter infection, sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea, pneumonia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22781923\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to fish, egg, soybean, or any other component of the formulation; severe hyperlipidemia or severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride concentrations &gt;1,000 mg/dL). <b>Note:</b> Although the manufacturer's labeling lists hypersensitivity to peanut protein as a contraindication, the product does not contain peanut protein. However, a low risk of cross-reactivity between soy and peanuts may exist.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Severe hepatic insufficiency; severe blood coagulation disorders; severe renal insufficiency without access to hemofiltration or dialysis; acute shock; acute pulmonary edema; hyperhydration; decompensated cardiac insufficiency; unstable conditions (eg, severe post-traumatic conditions, uncompensated diabetes mellitus, acute MI, CVA, embolism, metabolic acidosis, severe sepsis, hypotonic dehydration)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22781924\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fat overload syndrome: Although rare, a reduced or limited ability to metabolize lipids accompanied by prolonged plasma clearance resulting in a sudden deterioration in the patient's condition accompanied by fever, anemia, leukopenia, thrombocytopenia, coagulation disorders, hyperlipidemia, liver fatty infiltration (hepatomegaly), deteriorating liver function, and CNS (eg, coma) may occur; usually reversible upon discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic effects: Although the exact etiology is unknown and likely multifactorial, parenteral nutrition associated liver disease (PNALD) has been reported in patients receiving parenteral nutrition for extended periods of time, especially preterm infants, and can present as cholestasis or steatohepatitis, fibrosis and cirrhosis, possibly leading to hepatic failure; cholecystitis and cholelithiasis have also been observed. Consider discontinuation or dose reduction in patients who develop abnormal LFTs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Contains soybean oil, fish oil, and egg phospholipids; hypersensitivity reactions may occur. Cross sensitivity has been observed between soybean and peanut. Discontinue use immediately if a reaction occurs and treat appropriately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypertriglyceridemia: Impaired lipid metabolism with hypertriglyceridemia may occur in conditions such as inherited lipid disorders, obesity, diabetes mellitus, and metabolic syndrome. Obtain baseline serum triglycerides before initiating therapy, at the time of each dosage increase, and regularly throughout treatment. In adults with triglycerides &gt;400 mg/dL, reduce the dose and monitor triglycerides.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Refeeding syndrome: Refeeding severely undernourished patients with parenteral nutrition may result in the refeeding syndrome (eg, intracellular shift of potassium, phosphorus, and magnesium as the patient becomes anabolic); thiamine deficiency and fluid retention may also develop. Carefully monitor severely undernourished patients and slowly increase their nutrient intakes, while avoiding overfeeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anemia: The use of fat emulsion has been associated with anemia likely due to hemodilution (Zellner 1967). Use with caution in patients with anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bleeding disorders: Use with caution in patients with bleeding disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fat embolism: Use with caution in patients who may be at danger for fat embolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pancreatitis: Use with caution in patients with pancreatitis without hyperlipidemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; may contain aluminum, which may accumulate following prolonged administration in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Respiratory disease: Use with caution in patients with respiratory disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Toxicity secondary to highly lipid soluble substances: Hemodynamic and other instability: Successful resuscitation following the administration of fat emulsion has been reported in animal studies and several human case reports in which cardiovascular toxicity was unresponsive to conventional resuscitation and antidotal measures. Successful resuscitation following the administration of fat emulsion has been reported in pediatric patients (Fuzaylov 2010; Ludot 2008; Shah 2009; Wong 2010). Additional information is available at http://www.lipidrescue.org. Consider use when toxicity secondary to a highly lipid soluble substance is likely and conventional methods are unsuccessful. Continue CPR throughout treatment with lipid emulsion. Consultation with a medical toxicologist or poison control center is highly recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Energy expenditure and requirements may be lower in elderly patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; <b>Pediatric [US Boxed Warning]: Deaths in preterm infants following administration of fat emulsion have been reported; autopsy findings included intravascular fat accumulation in the lungs. Premature infants, low-birth-weight infants, and small-for-gestational-age infants clear intravenous fat emulsion poorly and have increased free fatty acid plasma levels following fat emulsion infusion.</b> The safe and effective use in pediatric patients, including preterm infants, has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Aluminum: May contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal impairment. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration: The too-rapid administration of fat emulsion can cause fluid and/or fat overloading, resulting in dilution of serum electrolyte concentrations, overhydration, congested states, pulmonary edema, impaired pulmonary diffusion capacity, or metabolic acidosis; hourly infusion rate should be as low as possible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Simultaneous infusion of a carbohydrate/amino acid solution is recommended to minimize the risk of metabolic acidosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Three-in-one mixtures: Lipid emulsion in a three-in-one mixture may obscure the presence of a precipitate; follow compounding guidelines, especially for calcium and phosphate additions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F47086803\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F47086800\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=110860&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Fat Emulsion (Fish Oil and Plant Based) may diminish the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22781921\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Severe maternal malnutrition may cause adverse events to the fetus/neonate. Indications for fat emulsion therapy in pregnant women are the same as in nonpregnant women. The ASPEN guidelines for parenteral and enteral nutrition state that intravenous fat emulsion may be used safely in pregnant women to provide calories and prevent essential fatty acid deficiency (ASPEN Guidelines 2002). Fat emulsion therapy has been used successfully in the resuscitation of a pregnant female with suspected bupivacaine toxicity (Spence 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22874959\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;\">Monitor for signs and symptoms of infection (including vascular access device complications); fluid and electrolyte status; serum osmolarity; blood glucose; blood counts (including platelets and coagulation parameters); signs and symptoms of essential fatty acid deficiency, fat overload, refeeding syndrome, and/or hypersensitivity reactions.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Monitor hepatic and renal function tests periodically. Monitor triglycerides before initiation of therapy and at least weekly during therapy or until triglycerides are stable and when changes are made in the amount of fat administered (ASPEN Guidelines 2002); monitor especially closely in premature infants, septic infants, and patients with pancreatitis or hepatic disease.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">At the onset of therapy, the patient should be observed for any immediate allergic reactions such as dyspnea, cyanosis, and fever. Monitor line site for signs and symptoms of infection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22781927\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fat emulsion is metabolized and utilized as an energy source; provides fatty acids (linoleic acid, oleic acid, caprylic acid, palmitic acid, capric acid, stearic acid, and alpha linolenic acid) and omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) necessary for normal structure and function of cell membranes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In toxicity secondary to highly lipid soluble substances, exogenous lipids provide an alternative source of binding (Rowlingson 2008), commonly known as the &quot;lipid sink&quot; effect. High lipid partition constant and large volumes of distribution are good predictors of success when using lipid therapy (French 2011). Lipid administration may also affect the heart in a metabolically advantageous way by improving fatty acid transport (Weinberg 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22781929\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Fatty acids, phospholipids, and glycerol are metabolized by cells to adenosine triphosphate (ATP), carbon dioxide, and water</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Biliary (phospholipids)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22874960\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Smoflipid contains 0.163 to 0.225 mg/mL of all-rac-&alpha;-tocopherol; take into consideration the amount of &alpha;-tocopherol provided by Smoflipid when determining the need for additional supplementation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48851915\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Emulsion</b> (SMOFlipid Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20% (250 mL): $27.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50168918\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Smoflipid (AR, AT, CR, CZ, DE, DK, DO, EE, ES, FR, GT, HK, HN, HR, HU, IL, KR, LB, LT, LV, MX, NI, NO, NZ, PA, PL, PT, RO, SI, SK, SV, UA, UY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ASPEN Board of Directors and the Clinical Guidelines Task Force. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. <i>JPEN J Parenter Enteral Nutr</i>. 2002;26(1 Suppl):1-138.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-pediatric-drug-information/abstract-text/11841046/pubmed\" target=\"_blank\" id=\"11841046\">11841046</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Biesboer AN, Stoehr NA. A product review of alternative oil-based intravenousfat emulsions. <i>Nutr Clin Pract</i>. 2016;31(5):610-618.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-pediatric-drug-information/abstract-text/27528126/pubmed\" target=\"_blank\" id=\"27528126\">27528126</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Deshpande G, Simmer K, Deshmukh M, Mori TA, Croft KD, Kristensen J. Fish oil (SMOFlipid) and olive oil lipid (Clinoleic) in very preterm neonates. <i>J Pediatr Gastroenterol Nutr</i>. 2014;58(2):177-182.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-pediatric-drug-information/abstract-text/24048161/pubmed\" target=\"_blank\" id=\"24048161\">24048161</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    French D, Smollin C, Ruan W, et al. Partition constant and volume of distribution as predictors of clinical efficacy of lipid rescue for toxicological emergencies. <i>Clin Toxicol</i>. 2011;49(9):801-809.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-pediatric-drug-information/abstract-text/21981684/pubmed\" target=\"_blank\" id=\"21981684\">21981684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuzaylov G, Ying B, Tang Y, Sethna NF. Successful resuscitation after inadvertent intravenous injection of bupivacaine in an adolescent. <i>Paediatr Anaesth</i>. 2010;20(10):958-959.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-pediatric-drug-information/abstract-text/20849502/pubmed\" target=\"_blank\" id=\"20849502\">20849502</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goulet O, Ant&eacute;bi H, Wolf C, et al. A new intravenous fat emulsion containing soybean oil, medium-chain triglycerides, olive oil, and fish oil: a single-center, double-blind randomized study on efficacy and safety in pediatric patients receiving home parenteral nutrition. <i>JPEN J Parenter Enteral Nutr</i>. 2010;34(5):485-495.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-pediatric-drug-information/abstract-text/20852176/pubmed\" target=\"_blank\" id=\"20852176\">20852176</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine). <i>Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients)</i>. Washington, DC: The National Academies Press, 2005.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practice (ISMP). IV fat emulsion needs a filter. <i>ISMP Medication Safety Alert</i>. January 14, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ludot H, Tharin JY, Belouadah M, Mazoit JX, Malinovsky JM. Successful resuscitation after ropivacaine and lidocaine-induced ventricular arrhythmia following posterior lumbar plexus block in a child. <i>Anesth Analg</i>. 2008;106(5):1572-1574.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-pediatric-drug-information/abstract-text/18420879/pubmed\" target=\"_blank\" id=\"18420879\">18420879</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mirtallo J, Canada T, Johnson D, et al. Task Force for the Revision of Safe Practices for Parenteral Nutrition: Safe practices for parenteral nutrition. <i>JPEN J Parenter Enteral Nutr</i>. 2004;28(6):S39-S70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-pediatric-drug-information/abstract-text/15568296/pubmed\" target=\"_blank\" id=\"15568296\">15568296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Muhammed R, Bremner R, Protheroe S, Johnson T, Holden C, Murphy MS. Resolution of parenteral nutrition-associated jaundice on changing from a soybean oil emulsion to a complex mixed-lipid emulsion. <i>J Pediatr Gastroenterol Nutr</i>. 2012;54(6):797-802.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-pediatric-drug-information/abstract-text/22157927/pubmed\" target=\"_blank\" id=\"22157927\">22157927</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park HW, Lee NM, Kim JH, Kim KS, Kim SN. Parenteral fish oil-containing lipid emulsions may reverse parenteral nutrition-associatedcholestasis in neonates: a systematic review and meta-analysis. <i>J Nutr</i>. 2015;145(2):277-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-pediatric-drug-information/abstract-text/25644348/pubmed\" target=\"_blank\" id=\"25644348\">25644348</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowlingson JC. Lipid Rescue: A Step Forward in Patient Safety? Likely So! <i>Anesth Analg</i>. 2008;106(5):1333-1336.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-pediatric-drug-information/abstract-text/18420839/pubmed\" target=\"_blank\" id=\"18420839\">18420839</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Savini S, D'Ascenzo R, Biagetti C, et al. The effect of 5 intravenous lipid emulsions on plasma phytosterols in preterm infantsreceiving parenteral nutrition: a randomized clinical trial. <i>Am J Clin Nutr</i>. 2013;98(2):312-318.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-pediatric-drug-information/abstract-text/23761482/pubmed\" target=\"_blank\" id=\"23761482\">23761482</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shah S, Gopalakrishnan S, Apuya J, Shah S, Martin T. Use of Intralipid in an infant with impending cardiovascular collapse due to local anesthetic toxicity. <i>J Anesth</i>. 2009;23(3):439-441.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-pediatric-drug-information/abstract-text/19685131/pubmed\" target=\"_blank\" id=\"19685131\">19685131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Skouroliakou M, Konstantinou D, Agakidis C, et al. Cholestasis, bronchopulmonary dysplasia, and lipid profile in preterm infants receivingMCT/&omega;-3-PUFA-containing or soybean-based lipid emulsions. <i>Nutr Clin Pract</i>. 2012;27(6):817-824.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-pediatric-drug-information/abstract-text/22878361/pubmed\" target=\"_blank\" id=\"22878361\">22878361</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smoflipid (fat emulsion [fish oil based]) [product information]. Cheshire, UK: Fresenius Kabi Limited; November 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smoflipid (fat emulsion [fish oil based]) [product information]. Mount Kuring-gai NSW, Australia: Fresenius Kabi Australia Pty Limited; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smoflipid (fat emulsion [fish oil based]) [product information]. Uppsala, Sweden: Fresenius Kabi; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spence AG. Lipid reversal of central nervous system symptoms of bupivacaine toxicity. <i>Anesthesiology</i>. 2007;107(3):516-517.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-pediatric-drug-information/abstract-text/17721262/pubmed\" target=\"_blank\" id=\"17721262\">17721262</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Food and Drug Administration (FDA). Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77,792-77,793.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weinberg GL, Ripper R, Murphy P, et al. Lipid infusion accelerates removal of bupivacaine and recovery from bupivacaine toxicity in the isolated rat heart. <i>Reg Anesth Pain Med</i>. 2006;31(4):296-303.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-pediatric-drug-information/abstract-text/16857549/pubmed\" target=\"_blank\" id=\"16857549\">16857549</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wong GK, Joo DT, McDonnell C. Lipid resuscitation in a carnitine deficient child following intravascular migration of an epidural catheter. <i>Anaesthesia</i>. 2010;65(2):192-195.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-pediatric-drug-information/abstract-text/19849674/pubmed\" target=\"_blank\" id=\"19849674\">19849674</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zellner DC, Iacono JM. &quot;Dilution anemia&quot; associated with multiple infusions of a fat emulsion. <i>Am J Clin Nutr</i>. 1967;20(7):766-776.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-pediatric-drug-information/abstract-text/6036266/pubmed\" target=\"_blank\" id=\"6036266\">6036266</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 110860 Version 9.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F48869238\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F47022752\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F22549120\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F22874952\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F49160709\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F22874957\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F47022753\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F47022751\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F22874958\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F22781926\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F22874953\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F22801482\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F22781923\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F22781924\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F47086803\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F47086800\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F22781921\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F22874959\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F22781927\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F22781929\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F22874960\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F48851915\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F50168918\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/110860|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-drug-information\" class=\"drug drug_general\">Fat emulsion (soybean, medium-chain triglyceride, olive, and fish oils; Smoflipid): Drug information</a></li><li><a href=\"topic.htm?path=fat-emulsion-soybean-medium-chain-triglyceride-olive-and-fish-oils-smoflipid-patient-drug-information\" class=\"drug drug_patient\">Fat emulsion (soybean, medium-chain triglyceride, olive, and fish oils; Smoflipid): Patient drug information</a></li></ul></div></div>","javascript":null}